Imagenebio, Stock Performance
| IMA Stock | 5.90 0.08 1.34% |
The company retains a Market Volatility (i.e., Beta) of 1.36, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ImageneBio, will likely underperform. At this point, ImageneBio, has a negative expected return of -0.39%. Please make sure to check out ImageneBio,'s potential upside, day median price, and the relationship between the treynor ratio and accumulation distribution , to decide if ImageneBio, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days ImageneBio, has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in January 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 121.2 M | |
| Total Cashflows From Investing Activities | -34.9 M |
ImageneBio, | Build AI portfolio with ImageneBio, Stock |
ImageneBio, Relative Risk vs. Return Landscape
If you would invest 778.00 in ImageneBio, on September 25, 2025 and sell it today you would lose (188.00) from holding ImageneBio, or give up 24.16% of portfolio value over 90 days. ImageneBio, is generating negative expected returns assuming volatility of 3.068% on return distribution over 90 days investment horizon. In other words, 27% of stocks are less volatile than ImageneBio,, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
ImageneBio, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImageneBio,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ImageneBio,, and traders can use it to determine the average amount a ImageneBio,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1278
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMA |
Based on monthly moving average ImageneBio, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImageneBio, by adding ImageneBio, to a well-diversified portfolio.
ImageneBio, Fundamentals Growth
ImageneBio, Stock prices reflect investors' perceptions of the future prospects and financial health of ImageneBio,, and ImageneBio, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImageneBio, Stock performance.
| Operating Margin | (5.01) % | ||||
| Current Valuation | 111.51 M | ||||
| Shares Outstanding | 11.18 M | ||||
| Price To Sales | 21.32 X | ||||
| Revenue | 3.5 M | ||||
| EBITDA | (35.47 M) | ||||
| Total Debt | 7.52 M | ||||
| Book Value Per Share | (0.43) X | ||||
| Cash Flow From Operations | (46 M) | ||||
| Earnings Per Share | (4.33) X | ||||
| Total Asset | 141.51 M | ||||
| Retained Earnings | (331.62 M) | ||||
About ImageneBio, Performance
By analyzing ImageneBio,'s fundamental ratios, stakeholders can gain valuable insights into ImageneBio,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImageneBio, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImageneBio, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about ImageneBio, performance evaluation
Checking the ongoing alerts about ImageneBio, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImageneBio, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImageneBio, generated a negative expected return over the last 90 days | |
| ImageneBio, has high historical volatility and very poor performance | |
| ImageneBio, was previously known as IKNA Old and was traded on NASDAQ Exchange under the symbol IKNA. | |
| The company reported the last year's revenue of 3.5 M. Reported Net Loss for the year was (49.23 M) with profit before taxes, overhead, and interest of 4.3 M. | |
| ImageneBio, generates negative cash flow from operations | |
| About 14.0% of the company shares are held by company insiders |
- Analyzing ImageneBio,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImageneBio,'s stock is overvalued or undervalued compared to its peers.
- Examining ImageneBio,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImageneBio,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImageneBio,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImageneBio,'s stock. These opinions can provide insight into ImageneBio,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ImageneBio, Stock analysis
When running ImageneBio,'s price analysis, check to measure ImageneBio,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImageneBio, is operating at the current time. Most of ImageneBio,'s value examination focuses on studying past and present price action to predict the probability of ImageneBio,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImageneBio,'s price. Additionally, you may evaluate how the addition of ImageneBio, to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments |